Anocca is a drug and immunotherapy developer aiming to uncover the therapeutic potential of T-cell immunity.
Anocca provides services like biotechnology, immunotherapeutics, drug discovery, drug development, and immunology services.The company does precise and efficient analysis of T-cell biology, which is required to deliver a variety of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas, including cancer, assisting the life sciences sector in developing a variety of therapies and vaccination strategies.Anocca was established on October 23, 2014 by Reagan Jarvis in Södertälje, Vasternorrlands Lan.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 21, 2022 | Debt Financing | €25M | 1 |
European Investment Bank
|
— | Detail |
| Jul 22, 2021 | Series B | $47M | 5 | — | — | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
European Investment Bank
|
Yes | Debt Financing |
Harald Mix
|
— | Series B |
Nidoco
|
— | Series B |
|
|
— | Series B |
Robert Andreen
|
— | Series B |
|
|
— | Series B |